Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer

Asian J Androl. 2019 Nov-Dec;21(6):635-636. doi: 10.4103/aja.aja_9_19.

Authors

Akihiro Yano¹, Makoto Kagawa¹, Hideki Takeshita¹, Yohei Okada¹, Makoto Morozumi¹, Satoru Kawakami¹

Affiliation

¹ Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Androgen Antagonists / therapeutic use*
Biomarkers, Tumor / blood
Dehydroepiandrosterone Sulfate / blood*
Humans
Male
Middle Aged
Prostatic Neoplasms / blood
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / mortality
Prostatic Neoplasms, Castration-Resistant / blood
Prostatic Neoplasms, Castration-Resistant / diagnosis
Prostatic Neoplasms, Castration-Resistant / drug therapy
Prostatic Neoplasms, Castration-Resistant / mortality
Survival Analysis
Treatment Outcome

Substances

Androgen Antagonists
Biomarkers, Tumor
Dehydroepiandrosterone Sulfate